The Cross Talk of MicroRNAs and SATB2 Signaling Pathway in Osteogenesis in the Context of Dental Implants

Alsaif, Saad; Alrashidy, Mousa; Al Dossary, Saeed

Volume 0 - Int J Mol Cell Med (Inprees) Int J Mol Cell Med 2025, 0 - Int J Mol Cell Med (Inprees): 0-0 | Back to browse issues page

Mendeley

Zotero

RefWorks

Alsaif S, Alrashidy M, Al Dossary S. The Cross Talk of MicroRNAs and SATB2 Signaling Pathway in Osteogenesis in the Context of Dental Implants. Int J Mol Cell Med 2025;
URL: http://ijmcmed.org/article-1-2600-en.html

The Cross Talk of MicroRNAs and SATB2 Signaling Pathway in Osteogenesis in the Context of Dental Implants

Saad Alsaif¹

, Mousa Alrashidy²

, Saeed Al Dossary³

1- Restorative Department Prince Abdulrahman Advanced Dental Institute, Riyadh, Saudi Arabia , saadalsaif48@gmail.com
2- Restorative Department Prince Abdulrahman Advanced Dental Institute, Riyadh, Saudi Arabia
3- 1. Restorative Department, Prince Abdulrahman Advanced Dental Institute, Riyadh, Saudi Arabia.

Abstract: (339 Views)

Dental implant integration is dependent on osteogenesis driven by the transcription factor SATB2, which regulates osteogenic genes. MicroRNAs (miRNAs) modulate SATB2 and influence bone formation. This review evaluates miRNA-SATB2 interactions, non-coding RNAs, and biomaterials in dental implant osseointegration.
A critical review of studies from 2015 to 2025 was conducted to elucidate miRNA-SATB2 interactions and their impact on osteogenesis.
Inhibitory miRNAs (e.g., miR-31, miR-140-5p) suppress SATB2 via the Wnt/β-catenin or SIRT1/Smad3 pathways and reduce osteoblast differentiation. Promoter miRNAs (e.g., miR-17-5p, miR-27a-5p) enhance SATB2 through BMP/Smad signaling. Non-coding RNAs (e.g., lncRNA H19, hsa_circ_0007292) inhibit miRNAs affecting cancellous bone and promote osteogenesis. Biomaterials such as collagen/nanohydroxyapatite (Col/nHA) scaffolds and comorbidities (e.g., osteoporosis) influence outcomes. Inconsistent miRNA roles and limited in vivo data are key gaps.
miRNA- SATB2 interactions are critical for implant success. Patient-specific miRNA profiling and targeted therapies hold promise, pending clinical validation.